GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Capex-to-Operating-Cash-Flow

Entheon Biomedical (XCNQ:ENBI) Capex-to-Operating-Cash-Flow : 0.00 (As of Aug. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Entheon Biomedical's Capital Expenditure for the three months ended in Aug. 2024 was C$0.00 Mil. Its Cash Flow from Operations for the three months ended in Aug. 2024 was C$-0.07 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Entheon Biomedical Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Entheon Biomedical's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Capex-to-Operating-Cash-Flow Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial - - - - -

Entheon Biomedical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Entheon Biomedical's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Entheon Biomedical's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entheon Biomedical's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Capex-to-Operating-Cash-Flow falls into.



Entheon Biomedical Capex-to-Operating-Cash-Flow Calculation

Entheon Biomedical's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Nov. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.36
=N/A

Entheon Biomedical's Capex-to-Operating-Cash-Flow for the quarter that ended in Aug. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.071
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entheon Biomedical  (XCNQ:ENBI) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Entheon Biomedical Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Entheon Biomedical Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to treat addiction and substance use disorders.
Executives
Brian Jahns Senior Officer

Entheon Biomedical Headlines

No Headlines